2025 End of Year Update

When we started Dash, we were focused on delivering speed for sponsors. We didn’t expect to grow this fast ourselves! 2025 has been a very exciting year.

Our goal at Dash is to transform how bioanalysis outsourcing works in order to accelerate drug development timelines for sponsors, and we made incredible progress toward that goal this year. We built a truly exceptional team of scientists and engineers to build our integrated robotic assay platforms. We brought online 5 different assay platforms: ELISA, MSD, qPCR, ddPCT, and targeted LC-MS. We have numerous customers using these platforms from small biotechs in early development to large commercial pharmas, and we’ve consistently shown turnaround time of results of just a few days—10 times faster than industry norms.

We’re also disrupting the pricing model of bioanalysis with our transparent, fixed cost approach. You can find our pricing right on our website. No multi-week quote process with numerous meetings with salespeople and no NDAs required to see a number. Then we went even further and released a self-service quoting tool to let sponsors create their own cost estimates. Customers are always surprised we share pricing this way, but it’s part of our commitment to transform bioanalysis and unlock sponsors.

And we’ve done all of this out of our pilot lab. Well, we have some even more exciting news. We’re in the middle of moving to a massive new 24k sq ft lab in Waltham, which will be operational in January. This expanded space gives us room to scale our existing assay platforms as well as add new ones. First up, and pictured here, is our next capability coming online in our new facility: high-resolution LC-MS. This platform will allow us to analyze proteins, nucleic acids, and other large molecules with the sensitivity of LC-MS.

We’re excited for what the future holds!